Orfiril (Sodium Valproate)

Sodium valproate increases the level of the inhibitory neurotransmitter GABA, blocks voltage‑gated sodium channels, and inhibits T‑type calcium currents. These actions collectively dampen neuronal excitability, helping to control seizures, stabilize mood, and reduce migraine frequency.

The dosage of Orfiril is individualized. A qualified prescriber determines the appropriate dose based on the patient’s age, weight, clinical condition, and response to therapy. Patients should follow the prescribing physician’s instructions and not adjust the dose on their own.

Sodium valproate is associated with a high risk of congenital malformations, especially neural‑tube defects, when used during pregnancy. It is generally avoided unless no safer alternative exists. Valproate is excreted in breast milk; breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the Orfiril product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with alternatives such as carbamazepine or lamotrigine, sodium valproate offers broad-spectrum seizure control and mood‑stabilising properties but carries a higher risk of hepatic and hematologic adverse effects. Choice of therapy depends on the specific seizure type, comorbidities, and individual patient tolerance.

Orfiril tablets should be stored at ambient temperature below 25 °C, in their original packaging, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources to maintain product stability.

Orfiril is supplied as oral tablets that are taken by mouth with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water; they are not intended for crushing, chewing, or sublingual use.

The most serious risks include severe liver injury, acute pancreatitis, life‑threatening blood disorders such as thrombocytopenia, hyperammonemic encephalopathy, and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for early signs of these conditions.

Orfiril is contraindicated in patients with known hypersensitivity to sodium valproate or any excipients, in individuals with severe hepatic disease, and in pregnant women unless no alternative therapy is available. Caution is also advised for patients with mitochondrial disorders such as POLG‑related disease.